[This review was originally posted at the Nieman Journalism Lab Cephalexin Dosage, on May 25, 2012.]
Facebook’s quick fall: A week ago, Facebook had just launched the largest, most buzzworthy initial public offering in years. And now, that IPO has already brought them a potentially massive lawsuit and a federal investigation. Aside from the whole “pocketing millions upon millions of dollars” thing, it’s been a brutal week for Facebook execs. Here’s what happened.
Facebook dominated the conversation online last week (GigaOM has a good roundup from last Friday’s IPO), and a lot of that wasn’t positive, kjøpe Cephalexin på nett, köpa Cephalexin online. As data from Pew’s Project for Excellence in Journalism showed, much of the chatter online, particularly on Twitter, was about Facebook as an overhyped (and overvalued) stock, Cephalexin Dosage. Those online observers may have been more right than they knew: As reports from Reuters, Business Insider (two posts), and The Wall Street Journaldetailed, Facebook was allegedly telling top investors they had overestimated their projected financial figures, all while publicly talking up their earning potential and even expanding their stock offering to the rest of us. The result, My Cephalexin experience, so far, has been a U.S. Securities and Exchange Commission investigation and a (potentially class-action) lawsuit from investors.
There were a number of good analyses of what went wrong — at The Guardian, Heidi Moore laid out the list of sins involved and concluded, “Facebook didn’t know how to work its own privacy settings for investors. It couldn’t figure out, essentially, who should know what.” Reuters’ Felix Salmon was more specific with his list of incompetents, Cephalexin for sale, declaring that the only winners in this game were the ones who didn’t play at all. The Big Picture’s Barry Ritholtz also ripped apart the debacle Cephalexin Dosage, .
The whole scandal still leaves open the question of what Facebook should, in fact, be valued at. At Technology Review, Michael Wolff was most provocative with his assessment, Cephalexin without a prescription, arguing that Facebook is just another business inextricably reliant on a fatally flawed online advertising model: “The crash will come. And Facebook—that putative transformer of worlds, which is, in reality, only an ad-driven site—will fall with everybody else,” he wrote. Harvard’s Doc Searls echoed Wolff’s thoughts about the brokenness of Facebook’s (and the web’s) ad model, and media consultant Terry Heaton countered that the broken industry isn’t the ad-supported web, Cephalexin reviews, but Madison Avenue’s insistence on the status quo on that web.
Others looked more closely at the future of Facebook’s services and of the social web more generally, Cephalexin Dosage. The Atlantic’s Alexis Madrigal wondered whether Facebook’s users would keep sharing and what would become of its native and mobile users, and ReadWriteWeb’s Dan Frommer examined the company’s four biggest risks (there’s mobile and advertising again!). There were other problems spotted: All Things D’s Peter Kafka looked at the continued decline of Facebook’s Social Reader apps, and The New York Times’ Nick Bilton contrasted Facebook and Twitter’s approaches to privacy. Tech blogger Dave Winer insisted that we can do better than Facebook, What is Cephalexin, while Slate’s Farhad Manjoo contended that Facebook has improved Silicon Valley.
The end of an era for New Orleans news: The American newspaper industry absorbed another big blow this week when the New Orleans Times-Picayune announced that it would drop back from daily publication to just three days a week, a change accompanied by the creation of a new corporate entity to run the paper and heavy layoffs — possibly a third of the newsroom. Cephalexin Dosage, The change will leave New Orleans as the largest city in the U.S. without a daily newspaper.
The news was broken by The New York Times’ David Carr, and according to the New Orleans alt-weekly Gambit, Times-Picayune employees learned of the paper’s fate through his report. (They later got this memo from the paper’s publisher.) All this came despite the fact that, Cephalexin schedule, as Jim Romenesko reported, the paper remains profitable. For some of the background on the paper — which is owned by Advance Publications, a division of the Newhouse publishing empire — see this post at the Columbia Journalism Review. (Advance also announced they’d be doing the same thing with three of its Alabama papers, led by the Birmingham News.)
Media analyst Ken Doctor has an extremely useful analysis of what exactly Advance/Newhouse is trying to accomplish with this move, and what perils it faces, Cephalexin Dosage. Doctor called the paper’s transition to digital a “forced march” because the paper simply isn’t ready for a digital transformation, particularly in terms of digital circulation. Purchase Cephalexin online, Others were similarly skeptical: The immediate comparison was to Advance’s 2009 transition of the daily Ann Arbor News to AnnArbor.com, and Forbes’ Micheline Maynard gave a bleak picture of what’s left of that news organization and the hole it’s left in the community.
Forbes’ John McQuaid, a former Times-Picayune reporter, described the way Advance’s web strategy has been “only lightly tethered to newsgathering,” and concluded that “with Advance, news has always been an adjunct to its vanilla branded sites, not something that is driving the internal business conversation, Cephalexin samples, and it shows.” And former Wall Street Journal writer (and Times-Picayune intern) Jason Fry said he doesn’t see any reason for optimism that Advance will get the web right in this case.
Free Press’ Josh Stearns noted that while the future-of-news world has been optimistically focused on experiments to sustain quality journalism in certain hubs like San Francisco, Chicago, and New York, they need to pay closer attention to mid-sized cities like New Orleans, where the infrastructure simply isn’t there to pick up the journalism being cut at major traditional news organizations.
What’s behind Buffett’s newspaper buy?: I briefly mentioned Warren Buffett’s purchase Cephalexin Dosage, late last week of 63 newspapers from Media General in last week’s review, but some smart commentary has come out about the deal since then (along with a few other pieces I missed at the time), so it’s worth touching on again. Cephalexin long term, Media analyst Ken Doctor did a sharp rundown of the deal, pointing out that the upside of Media General’s broadcast properties and the real estate involved with the newspapers Buffett’s buying should help buffer him from the inherent danger of buying a set of newspapers. Reuters’ Jack Shafer pointed out several of Buffett’s past bearish statements about newspapers, but said he’s most likely buying because he sees an undervalued asset, not for any sentimental reason.
The Columbia Journalism Review’s Justin Peters and The Washington Post’s Erik Wemple both explained why these papers might be surprisingly valuable for Buffett: While major metro dailies have taken a beating, smaller community newspapers in rural areas have weathered the digital storm fairly well so far, in part because of their monopoly on local news and the slower rates of broadband adoption there, online buy Cephalexin without a prescription.
Former journalism professor Philip Meyer made a similar point, arguing that Buffett is the type of buyer who’s happy with the new normal of lower profit margins for newspapers: “It looks like he is betting that the slide in newspaper earning power has leveled out. The Internet has done all the damage it can, and papers still make money.” PaidContent’s Jeff John Roberts looked at the economic sense Buffett’s paywall plan makes, while media consultant Dan Conover said he should be open to other non-paywall-based models, Cephalexin Dosage. Poynter’s Andrew Beaujon, meanwhile, said we may be ignoring another big reason for news org purchases like Buffett’s — they’re a platform for personal philosophies of how journalism should be done. Buffett did tell his new papers’ publishers that he would be hands-off with them, Cephalexin dosage, and that he expected to buy more small and mid-sized papers.
The bill, which was supposedly meant as a weapon against cyber-bullying and attacks against “local businesses and elected officials,” was predictably (and rightly) met with derision from scholars and those on the web. Columbia’s Tim Wu told The Guardian the bill was “an obvious first amendment violation, Cephalexin blogs,” and the bill was also ripped at sites like Techdirt and Animal. BetaBeat reported that some of the lawmakers involved with the bill were surprised by the blowback about it, while The Atlantic brought out a dissenting opinion, with a point/counterpoint on the value of anonymous online discourse.
— The Wall Street Journal reported on some of the ongoing struggles with AOL’s hyperlocal journalism project, Patch, Comprar en línea Cephalexin, comprar Cephalexin baratos, breaking the news that 20 Patch employees were being laid off and that one of AOL’s major investors is trying to get Patch killed, sold, or put into a joint venture. Jeff Bercovici of Forbes said it’s going to take a lot more cost-cutting or revenue-raising to get Patch to profitability by next year, and The Washington Post’s Erik Wemple said hyperlocal journalism’s business model doesn’t have room for executives in suits, Cephalexin Dosage.
— The New York Times’ public editor, Arthur Brisbane, will leave his position in September after two years, declining an optional third year. The Washington Post’s Erik Wemple, Cephalexin from canadian pharmacy, who broke the story, took the opportunity to criticize his most recent column, and Poynter’s Craig Silverman proposed five qualifications for the next public editor of the Times. Poynter also held a chat about the role of ombudsmen with Washington Post ombudsman Patrick Pexton and Reuters’ Jack Shafer.
— This week in Murdoch was a relatively quiet one. Cephalexin Dosage, News Corp. was reported to be considering spinning off its British newspapers — the Sun, the Times, and the Sunday Times — in order to preserve the rest of its media empire, something Murdoch denied but the Columbia Journalism Review’s Emily Bell saw as quite sensible. Here at the Lab, Ken Doctor examined what a trust for those papers might look like.
— A couple of interesting pieces of survey data discussed this week: The study that drew most of the headlines was one that looked at the political knowledge of audiences for various news outlets, finding NPR’s listeners to be the most informed and Fox News’ viewers to be the least informed. Another study found that about half of media professionals abandon websites when they hit a paywall.
— Finally, a couple of cool pieces on data journalism — Simon Rogers of The Guardian urged us to take on the punk “anyone can do it” mindset toward data journalism, and Alex Howard of O’Reilly Radar talked with former Guardian digital editor Emily Bell about her efforts to put data journalism into action with students at Columbia University.
Similar posts: Synthroid Dosage. Cipro For Sale. Cipro Dosage. Cheap Zoloft. Generic Bactrim. Real brand Cipro online.
Trackbacks from: Cephalexin Dosage. Cephalexin Dosage. Cephalexin Dosage. Cephalexin from canada. Cephalexin wiki. No prescription Cephalexin online.
[This review was originally posted at the Nieman Journalism Lab Glucophage No Rx, on March 4, 2011.]
Google's surgical strike against content farms: Two weeks after launching its site-blocking Chrome extension, Google made the central move in its fight against content farms by changing its algorithm to de-emphasize them in search results. The New York Times put the change in context, explaining the content farm phenomenon and its connection to Google. Search Engine Land's Danny Sullivan explained that Google is saying the changes only affect "scrapers" (sites that pull content from other sources), but that they're actually aimed at content farms, too. Glucophage trusted pharmacy reviews, And GigaOM's Mathew Ingram talked about why Google may be reluctant to publicly target content farms — because they run a lot of Google advertising.
A few early returns were good: TechCrunch approved of the change, and The Atlantic's Alexis Madrigal ran a test search comparing the old and new algorithms, finding that the information from the new one was "much, much better." Demand Media, the most prominent of the content farms, said it wasn't affected overall by the new formula, canada, mexico, india, though, as Henry Blodget of Business Insider noted, it's probably trying to wean itself off of Google reliance anyway.
In fact, it appears Demand Media may be telling the truth: Aaron Hall of SEO Book used Sistrix's data to point out that many of Demand Media's competitors were among the sites hardest hit by the change, while one of Demand's largest brands, eHow, actually got a boost. Hall implies that politics have played a role, and while there's nothing concrete suggesting that, the way the changes spared eHow does seem .., Glucophage No Rx. odd.
There's also bound to be plenty of collateral damage from the algorithmic shift, Glucophage recreational, and Wired looked at one Mac blog that's been nailed by the new formula (its Googlejuice was restored after Wired talked to Google about it). Danny Sullivan reported that Google hasn't made any significant changes to its new algorithm since rolling it out last week, though there are outlets to contact Google if you feel your site has been unfairly hurt.
Elsewhere in the conversation about search, The Columbia Journalism Review's Karen Stabiner gave an overview of the debate about search engine optimization: The anti-SEO crowd, led by the Washington Post's Gene Weingarten, worries that the SEO mindset will privilege the powerful and eventually kill off creativity in favor of numbingly literal language, taking Glucophage. Glucophage No Rx, The SEO evangelists, on the other hand, say it's just encouraging honesty and straightforwardness, something it's difficult to object to.
Facebook extends comments' reach: Facebook continued its integration with media content across the web this week with the launch of an updated comments system. Essentially, users can simultaneously post their comments on both a site and on Facebook, with subsequent comments under that thread posted to the site straight from Facebook. PBS MediaShift's Mark Glaser talked to Facebook's Justin Osofsky about the ins and outs of the new system, Online Glucophage without a prescription, and ReadWriteWeb noted that it has fewer features than the commenting update Facebook previewed last fall.
TechCrunch's Erick Schonfeld identified the two aspects of the updated system that will be most attractive to publishers. First, it requires commenters to use their real names, thus theoretically cutting down on trolls and spammers (this part, of course, has been available to publishers through Facebook commenting for a while), Glucophage No Rx. Second — and this is the new one — it extends the reach of a post, spreading into more Facebook news feeds and making it easier for more people to join in the conversation. This particularly excited Lehigh j-prof Jeremy Littau, who said it could create "a virtuous circle between community and content sharing."
There are downsides as well, and while media analyst Alan Mutter was optimistic about the social potential of the new system, he also pointed out that it will give Facebook even more information about its users, Glucophage pictures, which it won't be sharing with publishers. As GigaOM's Mathew Ingram noted, it's the same tradeoff publishers have been dealing with regarding Facebook for several years now: Does the value of tapping into Facebook's social potential outweigh the price of handing over commenting to a notoriously controlling company?
TBD's lessons — more startup, less ad reliance: TBD in its original form may have died last week, but the six-month-old Washington local news site continued to stimulate conversation this week. Where to buy Glucophage, Its station posted an ad for a new manager to head the site, and TBD's former manager, Jim Brady, talked with The Columbia Journalism Review about the site's model, framing the conflict there as not TV vs. web, but startup vs, Glucophage maximum dosage. legacy: Glucophage No Rx, "I think if we could do TBD with a pure startup mentality, and if we could fund it more with a V.C. or an angel kind of way, and if we didn’t have the legacy side to work with, then I think it would actually have a better chance to succeed."
Others posited similar reasons for TBD's demise: Web journalist Jane Stevens talked about a few causes centered on a lack of corporate commitment, and The Guardian's Emily Bell pinpointed TBD's inability to have its own ad sales team (an explanation with which Brady concurred). The debate over hyperlocal journalism, What is Glucophage, stirred by Alan Mutter last week, continued to simmer, with Robert Washburn of The Canadian Journalism Project defending it and Paul Gillin of Newspaper Death Watch saying we need to look at non-advertising-based business models for it, a point media consultant Dan Conover also made in more in-depth form at Xark.
Amid all the analyses of what went wrong at TBD, Mandy Jenkins, the social media manager there, buy Glucophage no prescription, took stock of what went right, noting four things other news orgs can take away from its tenure: organizational openness, self-promotion, opening info beyond the newsroom, and hiring for mindset over pedigree. Is Glucophage addictive, —
iPad, part deux: Apple made a few headlines by launching iPad 2, which is apparently kind of like the iPad, only it's the second edition. I'll entrust you to the care of Techmeme for all the details about the product itself and focus instead on what it means for publishers and the larger world of media, Glucophage No Rx. The Lab's Joshua Benton pointed out two implications in particular — the mounting evidence of an e-book explosion and the iPad's increasing usefulness for reporting.
Damon Kiesow of Poynter examined the latter point in some detail, looking at the iPad 2's specs from a content creation perspective, japan, craiglist, ebay, overseas, paypal. And Cory Bergman of Lost Remote looked at the device's increased video capability and predicted that it would help fuel a surge in multi-platform video consumption and production.
Elsewhere in mobile media, tech blogger John Gruber defended Apple's app subscription program by breaking down the arguments against it one by one. Glucophage No Rx, And in a smart counter to Gruber, the Lab's Joshua Benton said that while Apple obviously isn't a charity and the financial difficulties of publishers aren't its problem, the arrangement still isn't ideal. Both posts are among the sharpest takes on the issue I've read, so they're worth taking time to read through. Buy Glucophage from mexico, —
Reading roundup: What to read this weekend while firming up South by Southwest plans:
— In non-commenting Facebook news, Mashable's Vadim Lavrusik put together a great overview of the varied role of Facebook in journalism. And in non-Facebook commenting news, Los Angeles Times media reporter James Rainey made the case for requiring commenters to use their real names, while Mediaite's Alex Alvarez defended anonymous commenting, Glucophage from canadian pharmacy.
— Here at the Lab, Lois Beckett wrote two fascinating posts based on a talk by The New York Times' Gerry Marzorati — one on the future of long-form journalism, and the other on the Times' planned paywall. Two other thought-provoking pieces published here this week: One by Joshua Benton on language and viral content, and another by three data journalists on news organizations creating value out of the trust placed in them, Glucophage No Rx.
— Amy Gahran wrote three awesome primers on mobile media — one on mobile apps, another on the current mobile landscape, Online buying Glucophage hcl, and one on mobile media and PR.
— Knight fellow Jeremy Adam Smith shared results from a survey on how meaningful journalism is being funded. It's a gold mine of statistics and information about the state of the journalism ecosystem.
— It's a pretty well-worn discussion, but Frederic Filloux's analysis of why incremental change isn't enough to rescue the newspaper industry is as succinct a summary of the current situation as I've seen. Even if you've heard it all, his piece is a good refresher.
Similar posts: Armour No Rx. Tramadol Dosage. Cephalexin For Sale. After Synthroid. Buy Bactrim from canada. Cheap Cipro.
Trackbacks from: Glucophage No Rx. Glucophage No Rx. Glucophage No Rx. Doses Glucophage work. Online buy Glucophage without a prescription. Glucophage long term.